UK to offer Oxford AstraZeneca 30 alternative due to blood clotting concerns

The UK’s drug regulator says that since the risk balance is for adults, it would be appropriate to provide modern vaccines for Pfizer / Bionatech and younger ones.

Britain’s drug regulator said on Wednesday that the country would be offered the Oxford / AstraZeneca alternative in the 1930s. COVID-19 Even after the European Medicines Agency (EMA) concluded a “possible link” between the vaccine and rare clots, the vaccine has evolved with evidence of its rare blood clots.

The Medicine and Health Care Product Regulatory Agency (MHRA) says regular monitoring has concluded that the estrogenica vaccine rarely causes blood clots.

Its review found that by the end of March, 19 out of 799 people in the UK had died, including rare blood clots. The MHRA emphatically stated that the jabs have become icy and that this is not proof that the benefits of the vaccine can be protected. COVID-19» UK to offer Oxford AstraZeneca 30 alternative due to blood clotting concerns » WebLVN » The UK's drug regulator says that since the risk balance is for adults, it would be appropriate to provide modern vaccines for Pfizer / Bionatech and younger ones. To exceed the risk.

No effective medicine or vaccine is safe. Although clinical trials of the vaccine allow us to evaluate the general effects, very few rare effects are seen when the vaccine scale is used, says MHRA Chief Executive Officer DRS. Dr. June Ryan.

I would like to reiterate that it is extremely rare, “said Dr. Rhine.

He said that at risk for the elderly, the National Health Service (NHS) would recommend Pfizer / Biotech and modern vaccine alternatives for young people.

For those who have received the Oxford / AstraZeneca vaccine and have shown specific symptoms four days or more later, MHRA consultation should be discussed with their doctor.

These symptoms include severe headache, blurred vision, chest pain, swelling of the legs, shortness of breath, persistent abdominal pain or abnormal sores. The advice for those who experience blood clots and low levels of platelets after the first dose is that they should not be given a second dose.

Professor Jonathan Van-Tam, the Deputy Chief Medical Officer of England, described the latest developments as “curriculum reform”, which is not uncommon in the vaccination program.

The MHRA decision announced at the Virtual Briefing comes with a Virtual Briefing from the European Medicine Agency (EMA) in Amsterdam, which published a similar study and stated that the overall profit-risk of Oxford / Astringency jobs remained positive.

The EMA said that the EMA’s safety committee has decided that abnormal blood clots with low blood platelets should be listed as a very rare side effect of Vaxaviria (Oxford / Astrageneca vaccine).

Those who have been vaccinated should seek immediate medical attention if they have symptoms of blood clots and low blood platelet aggregation.

The EMA said that an analytical explanation for blood clotting and blood platelet aggregation is an immunity, which is sometimes seen in patients treated with heparin (heparin-induced thrombocytopenia, HET).

It has released ongoing new research and improvements to provide more information.

The EMA said it had reported in the European Union (EU) Drug Safety Database as of March 22, 2011 that 622 cases of cerebral venous sinus thrombosis and 24 cases of splenic vein thrombosis had been closely reviewed.

Newsletter Updates

Enter your email address below to subscribe to our newsletter

Leave a Reply